Ann: 510(k) Application Submission to U.S. FDA, page-67

agreed.

RHT
- have 5 approved FDA products. Not many biotechs that produce consistent positive cash flow, and are growing in assets and revenue yearly
- Management are very sound and keep capital expenditure to a minimum.
- substantial holder bought $2-3mill at 20c+ when SP was 10c
- applied for FDA in April for HepaFat-Al, an AI software that aids in managing liver disease and liver transplants. When I called up - management said they were “highly confident” in receiving FDA approval
- management of RHT are sound and I’m guessing FDA have an amazing relationship with them for all their 5 products to have received FDA approval coupled by the fundamentals of their products
- Discl: bought 14c